论文部分内容阅读
近年来,自身免疫性甲状腺疾病(AITD)的基因治疗在一些动物实验中取得成功,如通过干预Na+/I-同向转运蛋白基因、甲状腺球蛋白基因、促甲状腺激素受体基因、白细胞介素-4基因等转基因治疗Graves病,通过干预白细胞介素-10基因、Fas配体基因、肿瘤坏死因子相关凋亡诱导配体基因等转基因治疗自身免疫性甲状腺炎。此外,细胞毒性T淋巴细胞相关抗原4、T细胞受体、X染色体等基因异常也与AITD发病有关,其基因治疗有待开展。基因治疗有望成为治疗AITD的一种新途径。
In recent years, gene therapy of autoimmune thyroid disease (AITD) has succeeded in some animal experiments, such as intervention of Na + / I-cotransporter gene, thyroglobulin gene, thyrotropin receptor gene, interleukin -4 gene in Graves’ disease and treat autoimmune thyroiditis through intervention of interleukin-10 gene, Fas ligand gene and tumor necrosis factor-related apoptosis-inducing ligand gene transgene. In addition, cytotoxic T lymphocyte antigen 4, T cell receptor, X chromosome and other genetic abnormalities also associated with the pathogenesis of AITD, its gene therapy to be carried out. Gene therapy is expected to become a new way to treat AITD.